Berman Capital Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Berman Capital Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Buy	+2	New	+$879	﹤0.01%	1818

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Berman Capital Advisors's BTAI Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in BioXcel Therapeutics (BTAI) in Q3 2021: 2 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1818 among its holdings.

103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

Berman Capital Advisors held 2 shares of BioXcel Therapeutics worth $1K as of Q3 2021.
BioXcel Therapeutics was a new Berman Capital Advisors position in Q3 2021.
BioXcel Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1818 holding.
103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.